If there is one nutrient universally associated with pregnancy, it is folate. Nearly every prenatal vitamin contains it, every obstetrician recommends it, and public health campaigns have spent decades emphasizing its importance in preventing neural tube defects. On that much, the science is settled.
What is far less settled, and far less discussed, is which form of folate your prenatal actually contains and whether your body can use it effectively. Because while the terms "folate" and "folic acid" are often used interchangeably, they are not the same thing. And for a significant portion of the population, that difference may matter more than most people realize.
Folate, Folic Acid, and Methylfolate: Clearing Up the Confusion
Let's start with definitions, because the terminology alone causes considerable confusion among both consumers and practitioners.
Folate is a general term for vitamin B9, a water-soluble nutrient that occurs naturally in foods like leafy greens, legumes, eggs, and liver. In its natural dietary form, folate participates in a wide range of biological processes, including DNA synthesis, cell division, and amino acid metabolism. During pregnancy, the demand for folate increases substantially to support the rapid cell growth required for placental development and fetal tissue formation.
Folic acid is the synthetic form of vitamin B9. It is the version found in most fortified foods (such as enriched bread, cereal, and flour) and in the vast majority of over-the-counter prenatal vitamins. Folic acid does not occur in nature. It was developed as a stable, inexpensive compound for supplementation and food fortification, and it has been remarkably successful in reducing the incidence of neural tube defects at a population level since mandatory fortification began in the late 1990s.
Methylfolate, also known as 5-methyltetrahydrofolate or 5-MTHF, is the biologically active form of folate. It is the form your body actually uses at the cellular level. When you eat folate-rich foods or take a folic acid supplement, your body must convert that folate through a series of enzymatic steps before it can be used. The final and most critical step in that conversion is performed by an enzyme called methylenetetrahydrofolate reductase, commonly abbreviated as MTHFR. The end product of that conversion is methylfolate.
In other words, methylfolate is where all roads lead. It is the finished form your cells need for DNA methylation, homocysteine regulation, and neurotransmitter production. Folic acid is simply the starting material, and the journey from starting material to finished product is not equally efficient for everyone.
Why Conversion Efficiency Matters
Here is where things get interesting. The MTHFR enzyme, which is responsible for that final conversion step, is encoded by a gene that is subject to common variations in the population. These genetic variations, known as polymorphisms, can reduce the efficiency of the enzyme and, by extension, reduce how effectively a person converts folic acid into its usable form.
Research estimates that approximately 40 to 60 percent of the global population carries at least one copy of a common MTHFR polymorphism. For individuals who carry two copies (one from each parent), the reduction in enzyme efficiency can be more pronounced. Studies have shown that individuals with the most common homozygous variant have blood folate levels that are, on average, about 16 percent lower than those without the variant when given the same amount of folic acid.
To be clear, having a genetic variation that affects MTHFR activity does not mean folic acid is useless. The CDC has stated plainly that people with common MTHFR variants can still process folic acid, and that folic acid supplementation remains effective at raising blood folate levels regardless of genotype. The 2024 CDC guidance specifically notes that folic acid intake is more important than MTHFR genotype in determining blood folate status.
That said, the picture is more nuanced than a binary of "works" or "doesn't work." For a woman who is already at risk of suboptimal folate status due to diet, absorption issues, or the increased demands of pregnancy, even a modest reduction in conversion efficiency could make a meaningful difference. And because most people have never been tested for MTHFR variants and most providers do not routinely screen for them, many women may not know whether their bodies are converting folic acid optimally.
This is one of the reasons a growing number of researchers and clinicians have begun recommending methylfolate as the default form of supplemental folate, particularly during pregnancy. When you take methylfolate, you bypass the conversion process entirely. Your body receives the nutrient in its finished, ready-to-use form, regardless of your genetic profile.
What "Bioavailability" Actually Means in Plain Language
The word "bioavailability" comes up frequently in conversations about folate, but it is worth defining clearly because it is one of the most important concepts in supplement science.
Bioavailability refers to the proportion of a nutrient that, once consumed, actually reaches your bloodstream and becomes available for your body to use. A nutrient can be present in a supplement at the full listed dose, but if your body cannot absorb it efficiently or cannot convert it into its active form, you may not receive the full benefit.
Think of it this way. Imagine you order a package and it arrives at a distribution center in your city. That package is technically "in your area," but it is not in your hands. It still needs to be processed, sorted, and delivered to your door. If the delivery system is slow or inefficient, the package might sit in the warehouse for days. Bioavailability is the difference between the package arriving at the warehouse and the package arriving at your door.
Folic acid has good overall bioavailability compared to food folates. It is well absorbed in the gut and reliably raises serum folate levels in most people. However, it requires that multistep enzymatic conversion before it can participate in cellular processes. Methylfolate, by contrast, is already in its final form. It does not require conversion by MTHFR or any other enzyme. It is absorbed, it enters the bloodstream, and it goes to work.
A 2023 randomized trial of pregnant women in Canada found that supplementation with 5-MTHF was as effective as folic acid in maintaining maternal folate status, while reducing levels of unmetabolized folic acid in maternal plasma by approximately 50 percent. Unmetabolized folic acid, or UMFA, is a topic of growing interest in the research community. When the body receives more folic acid than it can convert at one time, the excess circulates in the blood in its unconverted form. The clinical significance of elevated UMFA is still being studied, but some researchers have raised questions about its potential effects on immune function and other metabolic processes.
The Case for Methylfolate in Prenatal Supplementation
Given what we know about genetic variability, conversion efficiency, and the heightened demands of pregnancy, why would a prenatal vitamin use folic acid instead of methylfolate? The answer, as with so many things in the supplement industry, comes down to cost, convention, and regulation.
Folic acid is the form that has been studied most extensively in large-scale neural tube defect prevention trials. It is the form used in mandatory food fortification programs around the world. And it is the form that regulatory bodies like the CDC and ACOG continue to recommend, in large part because of the strength and volume of the existing evidence base. These are reasonable positions grounded in decades of public health success.
However, the research supporting methylfolate as an effective and potentially advantageous alternative has grown substantially in recent years. A review published in the Georgetown Medical Review in 2024 examined the evidence and proposed a shift from folic acid to 5-MTHF supplementation during pregnancy, citing improved bioavailability, the ability to bypass genetic polymorphisms, and the avoidance of UMFA accumulation. A separate expert discussion published in the journal Reviews in Obstetrics and Gynecology noted that given the high prevalence of MTHFR polymorphisms and the importance of ensuring adequate folate during pregnancy, "l-methylfolate may be the best option to avoid blood folate deficiencies." That same review also found that women taking prenatal vitamins with methylfolate had significantly higher hemoglobin levels at delivery compared to those taking folic acid, suggesting a potential benefit for maternal anemia.
It is important to acknowledge that the CDC's current guidance does not recommend switching from folic acid to methylfolate. Their position is that folic acid is the only form of folate with direct evidence of neural tube defect prevention, and that recommendation is supported by large, well-conducted studies. This is a valid and conservative public health stance. But at the individual level, where a woman is choosing a prenatal for her own body and her own pregnancy, the calculation may look different. Many clinicians now view methylfolate as a reasonable, evidence-supported choice that offers at least equivalent efficacy with some potential advantages, particularly for the large segment of the population carrying MTHFR polymorphisms.
What Is Quatrefolic and Why Does It Appear on Some Labels?
If you have been reading prenatal vitamin labels, you may have noticed the trademarked ingredient name "Quatrefolic." This is the glucosamine salt of 5-MTHF, a patented form of methylfolate produced by Gnosis by Lesaffre. It is sometimes referred to as a "fourth generation" folate because of its place in the evolution of supplemental folate ingredients.
The advantage of Quatrefolic over earlier forms of methylfolate relates to stability and solubility. Earlier calcium salt forms of 5-MTHF were effective but could be less stable in certain formulation conditions. The glucosamine salt form was developed to improve water solubility and shelf stability, which matters for both manufacturers formulating products and consumers who want confidence that the nutrient listed on the label is actually present and active when they take it.
Quatrefolic delivers methylfolate in a form that requires no metabolic conversion. It is absorbed directly, enters the folate cycle without depending on MTHFR activity, and is suitable for individuals regardless of their genetic background. It is the form we use in Mothersense Prenatal+ because it represents the current standard for methylfolate ingredient quality.
How to Evaluate the Folate in Your Prenatal
When comparing prenatal vitamins, the folate line on the supplement facts panel deserves careful attention. Here are the key things to look for.
The form listed. Check whether the label says "folic acid," "folate (as folic acid)," or "folate (as L-5-methyltetrahydrofolate)" or a branded equivalent like Quatrefolic. The distinction matters. If the label lists only "folic acid," the product contains the synthetic form that requires full enzymatic conversion. If it lists methylfolate or 5-MTHF, the product contains the bioactive form.
The dose. The recommended intake of folate during pregnancy is 600 mcg DFE (dietary folate equivalents) per day, with many experts recommending that women begin supplementation with at least 400 mcg before conception. Some prenatal vitamins provide higher doses, which may be appropriate for women with a history of neural tube defects or other risk factors. Your healthcare provider can help determine the right dose for your situation.
DFE vs. mcg. You may notice some labels list folate in "mcg DFE" rather than simply "mcg." Dietary folate equivalents are a unit designed to account for the different absorption rates of food folates, folic acid, and supplemental methylfolate. Because folic acid taken on an empty stomach is absorbed at a higher rate than food folate, 1 mcg of folic acid equals 1.7 mcg DFE. When comparing products, make sure you are comparing the same unit.
Transparency. As with any supplement ingredient, the dose should be clearly stated on the label. If folate is buried inside a proprietary blend without a specified amount, you have no way of knowing whether you are getting a clinically meaningful dose.
The Bottom Line
Folate is nonnegotiable during pregnancy. It is essential for neural tube closure, DNA synthesis, and healthy cell division at a time when your body is building an entirely new human being. On this, every major medical organization agrees.
Where the conversation is evolving is around which form of folate best serves expecting mothers. Folic acid has a strong track record at the population level, and the public health achievements of food fortification programs are significant and well documented. At the same time, research into methylfolate has demonstrated that it is at least as effective at maintaining maternal folate status, does not depend on the MTHFR enzyme for activation, and avoids the accumulation of unmetabolized folic acid in the blood.
For a significant portion of the population, potentially up to half or more, a genetic variation quietly reduces the efficiency of folic acid conversion. Most of these individuals will never be tested. Most will never know. And for a woman who is pregnant or planning to become pregnant, the simplest way to ensure she is getting folate her body can readily use is to choose a prenatal that provides it in its already-active form.
We chose methylfolate for Mothersense Prenatal+ because we believe prenatal supplementation should account for the realities of human biology, not just the conventions of the supplement industry. Every ingredient in our formula is selected for its bioavailable form, backed by published research, and transparently dosed on the label.
If you have questions about which form of folate is right for you, we encourage you to bring this topic to your next prenatal appointment. Your healthcare provider can help you weigh the evidence and make a decision that fits your individual health profile.
This article is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting or changing any supplement regimen.
References
- Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academies Press; 1998. https://doi.org/10.17226/6015
- Scaglione F, Panzavolta G. Folate, Folic Acid and 5-Methyltetrahydrofolate Are Not the Same Thing. Xenobiotica. 2014;44(5):480–488. https://doi.org/10.3109/00498254.2013.845705
- Pietrzik K, Bailey L, Shane B. Folic Acid and L-5-Methyltetrahydrofolate: Comparison of Clinical Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics. 2010;49(8):535–548. https://doi.org/10.2165/11532990-000000000-00000
- Ferrazzi E, Tiso G, Di Martino D. Folic Acid Versus 5-Methyl Tetrahydrofolate Supplementation in Pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020;253:312–319. https://doi.org/10.1016/j.ejogrb.2020.06.012
- Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6S]-5-Methyltetrahydrofolate or Folic Acid Equally Reduces Plasma Total Homocysteine Concentrations in Healthy Women. American Journal of Clinical Nutrition. 2004;79(3):473–478. https://doi.org/10.1093/ajcn/79.3.473
- Cochrane KM, et al. Supplementation with (6S)-5-Methyltetrahydrofolic Acid Appears as Effective as Folic Acid in Maintaining Maternal Folate Status While Reducing Unmetabolised Folic Acid in Maternal Plasma. British Journal of Nutrition. 2023;130(7):1128–1137. https://doi.org/10.1017/S0007114523001733
- Henderson AM, Aleliunas RE, Loh SP, et al. L-5-Methyltetrahydrofolate Supplementation Increases Blood Folate Concentrations to a Greater Extent Than Folic Acid Supplementation in Malaysian Women. Journal of Nutrition. 2018;148(6):885–890. https://doi.org/10.1093/jn/nxy057
- Centers for Disease Control and Prevention. MTHFR Gene Variant and Folic Acid Facts. Updated 2024. https://www.cdc.gov/folic-acid/data-research/mthfr/index.html
- Bentley S, Hermes A, Phillips D, Daoud YA, Hanna S. Comparative Effectiveness of a Prenatal Medical Food to Prenatal Vitamins on Hemoglobin Levels and Adverse Outcomes: A Retrospective Analysis. Clinical Therapeutics. 2011;33(2):204–210. https://doi.org/10.1016/j.clinthera.2011.02.010
- Prinz-Langenohl R, Brämswig S, Tobolski O, et al. [6S]-5-Methyltetrahydrofolate Increases Plasma Folate More Effectively Than Folic Acid in Women with the Homozygous or Wild-Type 677C→T Polymorphism of Methylenetetrahydrofolate Reductase. British Journal of Pharmacology. 2009;158(8):2014–2021. https://doi.org/10.1111/j.1476-5381.2009.00492.x